Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

6.560 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 25,501
Open 6.560
Bid (Size) 6.160 (100)
Ask (Size) 6.300 (4,900)
Prev. Close 6.560
Today's Range 6.560 - 6.560
52wk Range 1.100 - 10.08
Shares Outstanding 25,938,064
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data
Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This... 
Via MarketMinute
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
From Immuneering Corporation
Via GlobeNewswire

Performance

YTD
+196.8%
+196.8%
1 Month
+4.5%
+4.5%
3 Month
+91.3%
+91.3%
6 Month
+424.8%
+424.8%
1 Year
+252.7%
+252.7%

More News

Read More
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Immuneering Stock Soared Over 40% After-Hours Today
Via Stocktwits
Immuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On Dips
Via Stocktwits
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Top movers in Wednesday's after hours session
Via Chartmill
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
From Immuneering Corporation
Via GlobeNewswire
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces Closing of $25 Million Private Placement
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
From Immuneering Corporation
Via GlobeNewswire
Top stock movements in today's session.
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Top movers analysis in the middle of the day on 2025-08-21: top gainers and losers in today's session.
Via Chartmill
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Immuneering Announces $25 Million Private Placement
From Immuneering Corporation
Via GlobeNewswire
Immuneering Posts Narrower Loss in Q2
Via The Motley Fool
Topics Intellectual Property
Curious about the stocks that are showing activity after the closing bell on Wednesday?
Via Chartmill
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire

Frequently Asked Questions

Is Immuneering Corporation - Class A Common Stock publicly traded?
Yes, Immuneering Corporation - Class A Common Stock is publicly traded.
What exchange does Immuneering Corporation - Class A Common Stock trade on?
Immuneering Corporation - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immuneering Corporation - Class A Common Stock?
The ticker symbol for Immuneering Corporation - Class A Common Stock is IMRX on the Nasdaq Stock Market
What is the current price of Immuneering Corporation - Class A Common Stock?
The current price of Immuneering Corporation - Class A Common Stock is 6.560
When was Immuneering Corporation - Class A Common Stock last traded?
The last trade of Immuneering Corporation - Class A Common Stock was at 11/03/25 04:00 PM ET
What is the market capitalization of Immuneering Corporation - Class A Common Stock?
The market capitalization of Immuneering Corporation - Class A Common Stock is 170.15M
How many shares of Immuneering Corporation - Class A Common Stock are outstanding?
Immuneering Corporation - Class A Common Stock has 170M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.